The metabolic syndrome-cancer axis: global research trends and clinical landscapes

By
Dianzhe Tian
Xinshi Li
Jiajie Lin
Zuyi Yang
Xinyu Zhao
Zixuan Hu
Haitao Zhao
Shunda Du
Shengzhi Liu
Lei Zhang
Yiyao Xu
Xin Lu
June 22, 2026
0 min

Frontiers In Endocrinology

Objective:

To identify trends and clarify the molecular pathways connecting metabolic syndrome (MetS) to cancer through bibliometric and bioinformatics analysis.

Approach:

Key Findings:

Research output grew mainly driven by China and the US, with Europe showing high collaborative centrality.
Thematic analysis shifted from isolated metabolic issues to integrated MetS phenotypes, cancer prognosis, and interventions.
Bioinformatics identified hub genes and pathways linking metabolic dysregulation with tumor development, particularly involving inflammation, insulin signaling, and metabolic reprogramming.

Interpretation:

The analysis supports a bidirectional link between MetS and cancer.

Limitations:

Current research on MetS-cancer comorbidity remains fragmented.
There is a lack of integrated, quantitatively informed frameworks in existing studies.

Conclusion:

Targeting metabolic dysfunction may improve treatment tolerance and outcomes.

The metabolic syndrome-cancer axis: global research trends and clinical landscapes

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

The metabolic syndrome-cancer axis: global research trends and clinical landscapes

Related Content

Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making

NOSIP overexpression promotes long-term persistence of CD8+ T cells during chronic infection

From ribosomopathies to therapeutic targets: ribosomal alterations in pediatric leukemogenesis and tumorigenesis